biocryst, Author at Biocryst - Page 3 of 10

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Hereditary Angioedema Patients Would Prefer Newer-Generation Oral Prophylaxis

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Managing Diagnosis, Treatment and Burden of Disease in Hereditary Angioedema Patients with Normal C1-Esterase Inhibitor

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Optimal Management of Hereditary Angioedema: Shared Decision-Making

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Meeting Patient Needs in Hereditary Angioedema Care

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Specific Targeting of Plasma Kallikrein for Treatment of Hereditary Angioedema: A Revolutionary Decade

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Oral Once-Daily Berotralstat for the Prevention of Hereditary Angioedema Attacks: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)
Informed Decision-Making in Hereditary Angioedema Prophylaxis

View Article

biocryst

February 12, 2025

Hereditary Angioedema (HAE)